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Abstract 
 
A. Objective: The objective of this selective EBM review is to determine whether or not 
intravenous Peramivir 300mg is effective and safe in treating seasonal influenza. 
 
B. Study Design: Review of two randomized controlled trials (RCTs) and one randomized open-
label study, all published in 2010, 2011, and 2014, respectively.  
 
C. Data sources: Two randomized controlled trials and one randomized open- label study were 
all researched through the use of PubMed and belonged to peer reviewed journals. 
 
D. Outcome(s) Measured: Primary efficacy endpoint analyzed was time to alleviation of 
symptoms measured by influenza symptom severity scale (ISS), a self-assessment four point 
scale.  The primary safety endpoint measure was incidence of adverse events. The Fischer’s 
exact test was used for intergroup comparison of the safety endpoint. 
 
E. Results: When comparing alleviation of symptoms in all three studies, 300mg Peramivir was 
as effective as 600mg Peramivir. Both Peramivir groups were superior to the efficacy of placebo. 
Analysis of safety, using adverse events, displayed no significant difference between 300mg 
Peramivir and comparison groups.  
 
F. Conclusions: After analysis of the three studies in this review, there is significant data to 
show 300mg Peramivir is effective and safe in treatment of seasonal influenza. 
 
G. Key Words: Influenza, Peramivir 
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1. Introduction 
 
Seasonal influenza is a viral respiratory infection that is highly contagious and in serious 
cases can lead to death. This paper evaluates two randomized controlled trials (RCTs) and one 
randomized open-label study comparing the efficacy and safety of intravenous Peramivir 300mg 
for the treatment of seasonal influenza.  
Seasonal influenza is easily transmittable and currently affects over 10% of the 
population in the United States.  It leads to 200,000 hospitalizations and approximately over 
25,000 deaths, per year, in the United States.
1
 Patients with an underlying chronic respiratory 
disease or who are elderly have a significantly increased chance of death if infected by the 
seasonal influenza virus, thus making prophylaxis an essential aspect in combating this virus.
1 
The CDC has conducted data research and found that approximately $10.4 billion is spent 
on direct medical expenses for influenza.
2
 The CDC estimates, that there exists almost an 87 
billion dollar economic burden from influenza in the United States.
 
According to the CDC, there 
are approximately 31.4 million outpatient visits for flu each year. 
2
 
The presentation and complications of influenza are known. Much research has been 
conducted to understand the different strains of influenza that affect the human population. It is 
unknown which strains will be affecting the population and when the flu season will occur for a 
given year. There are vaccines available yearly to attempt and determine the most likely strains 
that the population will be exposed to.  
Supportive care is the main treatment for uncomplicated patients which includes 
analgesics and rest. Antivirals are chosen for complicated or higher risk patients such as 
neuraminidase inhibitors (Oseltamivir and Zanamivir) and M2 inhibitors (Amantadine and 
Rimantidine).
3 
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Most influenza cases are self-limiting thus the medications mentioned help combat the 
virus in those at high risk or complicated cases.
3
 The medications are effective for improvement 
of symptoms but do not cure the patient. Neuraminidase inhibitors are able to combat surface 
antigens of the virus.
3
 An issue affecting the treatment of influenza before the consideration of 
Peramivir, is the lack of options for route of administration.
1
 The neuraminidase inhibitors 
approved in the United States before Peramivir are Oseltamivir and Zanamivir.
3
 Oseltamivir and 
Zanamivir are only available as oral or inhalation, respectively.
3
 Peramivir can have the potential 
to be an effective choice from the neuraminidase inhibitors due to its unique characteristic of 
being intravenously administered.
1
 If Peramivir can prove to be effective and safe in treating 
influenza, it can provide a unique option for management.  
2. Objective  
 
The objective of this selective EBM review is to determine whether or not intravenous 
Peramivir 300mg is effective and safe in treating seasonal influenza. 
3. Methods  
 
For this review, specific criteria were met based on two randomized controlled trials 
(RCTs) and one randomized open-label study.  The target population utilized was patients ≥14 
years of age with influenza. The intervention analyzed was IV Peramivir 300mg which was 
further compared to IV Peramivir 600mg and Oseltamivir 75mg. The outcomes measured were 
time to alleviation of symptoms and incidence of adverse events. 
In the Ison et al
1
, an open label randomized study, the population consisted of 234 
hospitalized patients aged 14 to 92 with seasonal influenza from 59 hospitals in the US, Canada, 
Mexico, Australia, and New Zealand. The subjects screened were randomized evenly into two 
groups of 117 subjects, one group receiving 300mg Peramivir twice daily and the other 600mg 
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Peramivir once daily, respectively. The duration of treatment was for 5 days unless the PCR 
showed detectable virus on day 4 of the course. In this case, the treatment was allowed to 
continue for 5 more days, for a total of 10 days. 
1 
The study by Kohno et al
4
, a double blind randomized controlled trial, included 300 
previously healthy adults from 75 hospital centers in Japan. All subjects were aged 20-64 and 
recruited within 48 hours of influenza symptom onset. Influenza was confirmed in every subject 
by a positive rapid antigen test. The 300 subjects were randomized into three groups: 99 subjects 
receiving one single dose of 300mg intravenous Peramivir, 97 subjects receiving single dose of 
600mg intravenous Peramivir, and 100 subjects receiving an equivalent single dose of placebo.
4 
The Kohno et al
5
 study, a multicenter double blind randomized control trial, incorporated 
1,091 patients aged 20 years or older infected with influenza A or B virus. Subjects were from 
146 institutions located in Japan, South Korea, and Taiwan. The subjects were divided into three 
groups receiving a single dose of intravenous 300mg Peramivir, a single dose of intravenous 
600mg Peramivir, and 75mg of oral Oseltamivir twice daily for 5 days, respectively.
5
  
I personally, conducted all of the research for this review via Pubmed NCBI and had 
selected the articles by relevance to my clinical question and meeting the criteria of including 
patient oriented outcomes (POEMS). The key words used in the searches were “Influenza” and 
“Peramivir”. All of the articles were published in English and met the criteria of being published 
in peer reviewed journals. All of the studies included in this review were published within the 
past 15 years and at least 2 of the studies were RCTs. Studies that included patients less than 14 
years of age infected by seasonal influenza were excluded in the review. The statistics reported 
or used in the articles were p- values, relative risk increase (RRI), absolute risk increase (ARI), 
and numbers needed to harm (NNH). 
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Table 1 - Demographics & Characteristics of included studies 
Study Type #Pts Age 
(yrs) 
Inclusion 
criteria 
Exclusion criteria W/
D 
Interventions 
Ison
1             
(2014) 
Open 
Label  
RT 
234 ≥14 Patients from 
59 hospitals 
≥14 years of 
age with local 
influenza 
activity in the 
US, Canada, 
Mexico, 
Australia, and 
New Zealand 
Patients who required 
dialysis, altered 
neurological status, 
undergoing systemic 
chemotherapy or 
radiotherapy, recent 
hematopoietic stem cell 
or organ transplant, 
uncontrolled HIV,    pre-
existing chronic infection, 
had CF, pre-specified 
abnormalities on lab 
testing, women who were 
pregnant 
54 IV Peramivir 
300mg bid for     
5 days VS. 
IV Peramivir 
600mg qd for           
5 days 
 
Kohno
4
 
(2010) 
Double 
blind 
RCT 
300 20-
64 
Patients who 
were healthy 
adults aged 
20-64 with a 
positive 
influenza virus 
rapid antigen 
test recruited 
w/i 48hrs of 
onset 
 
Patients with respiratory 
dysfunction requiring 
medication, neurologic 
symptoms, active chronic 
illness or HIV, on 
hemodialysis, bacterial 
infection, hx with steroids 
use of anti-influenza virus 
drugs w/in past 7 days, hx 
of hypersensitivity or 
serious ADRs to anti- 
influenza drugs, pregnant/ 
breastfeeding 
4 IV Peramivir 
300mg qd for 1 
day VS. 
IV Peramivir 
600 mg qd for 1 
day 
 
 
Kohno
5 
(2011) 
 
 
 
 
 
 
 
 
 
 
 
 
Double 
blind 
RCT 
1091 ≥20 Patients aged 
20 years or 
older with 
influenza A  
or B virus 
infection in 
146 medical 
institutions in 
Japan, South 
Korea, and 
Taiwan 
Patients with impaired 
respiratory function, 
history of CHF, poorly 
controlled DM, 
immunosuppressive 
therapy or AIDS, renal 
disorder, ischemic heart 
disease or serious 
arrhythmia, corrected QT 
interval or bradycardia, 
required hospitalization, 
infection requiring 
systemic antibiotics 
8 IV Peramivir 
300mg qd for 1 
day VS. 
IV Peramivir 
600mg qd for 1 
day VS. 
Oseltamivir 
75mg bid for 5 
days 
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4. Outcomes  
  
 The outcomes addressed in this review consisted of patient oriented evidence found in the 
studies. In the Ison et al
1
 study, time to alleviation of symptoms was measured (in hours) using a 
four point scale that was filled out twice daily from day 1 to 9 then once daily until day 14. The 
scale was utilized by patients to rate their influenza symptoms, specifically cough, sore throat, 
nasal congestion, myalgia, headache, feverishness, and fatigue. The study measured adverse 
events by a daily checklist represented by a percentage.
1
  
 In Kohno et al
4 
and Kohno et al
5
, the primary efficacy endpoint analyzed was time to 
alleviation of symptoms. This was similarly recorded using a four point scale self-assessment, 
influenza symptom severity scale (ISS), rating the seven influenza symptoms mentioned above, 
twice daily for day 1 to 9 then once daily until day 14. The scale represented 0 meaning absent; 
1, mild; 2, moderate; 3, severe. Alleviation was considered the time (in hours) when all seven 
symptoms were rated “0” or “1” for at least 21.5 hours.4 Safety was assessed by the percentage 
of adverse events that occurred. They were rated using a graded scale of 1-3 according to the 
Division of AIDS table for grading adult and pediatric adverse events. Grades 1-3 represented 
mild, moderate, and severe ratings of the events, respectively and intergroup comparison was 
made using the Fischer’s exact test.4,5 
5. Results 
Each study compared 300mg Peramivir differently than the other. The open label study 
compared 300mg Peramivir, twice daily, to 600mg Peramivir, once daily alone, the Kohno et al
4 
RCT, compared both Peramivir groups, single dose, to placebo, and the Kohno et al
5 
RCT, 
compared both Peramivir groups to 75mg Oseltamivir. All studies were conducted in hospital 
settings involving subjects with confirmed influenza virus. Ison et al
1
, included the widest range 
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of patients ages (14-92) compared to Kohno et al
4
 (20-64) and Kohno
 
et al
5
 (20-80). Efficacy 
endpoint results in all studies were represented by continuous data and provided p-values and 
confidence intervals. Safety endpoints for all of the studies were able to be converted to 
dichotomous data thus relative risk increase (RRI), absolute risk increase (ARI), and numbers 
needed to harm (NNH) were calculated for this review for safety.  
In Ison et al
1
, 234 subjects were randomized into two groups, 300mg Peramivir and 
600mg Peramivir. Four withdrew before treatment and from the remaining population 127 
subjects had confirmed influenza thus leaving the intent to treat population to be 127 subjects. 
The study utilized the Kaplan-Meier method in order to measure time to alleviation of symptoms 
amongst the subjects. In the 300mg Peramivir group the median time in hours was 135 (95% 
CI:89,184) compared to the 600mg Peramivir group of 158 (95% CI:103,306). Safety was 
measured by documenting the number of adverse events experienced in the groups. The 300mg 
Peramivir group displayed 90 adverse events total (79% of the group) and the 600mg Peramivir 
group showed 85 adverse events total (73%). The relative risk increase calculated was 8% and 
the absolute risk increase was 6% (Table 2). The numbers needed to harm was calculated to be 
17. This means for every 17 patients who took Peramivir 300mg, there was one more incidence 
of an adverse event than those who took Peramivir 600mg. There were a total of 22 deaths 
recorded in the study, 8 deaths in the 300mg group and 14 deaths in the 600mg group.
1 
In Kohno et al
4
, 300 total subjects were randomly allocated to two groups receiving 
Peramivir (300mg or 600mg) and one group receiving placebo. Of the total 300 subjects, 4 
subjects had withdrawn from the study thus resulting in 296 subjects in the intent to treat 
population. Two subjects withdrew after allocation to groups but before treatment, one subject 
did not have any symptom assessment data, and one subject lacked laboratory confirmed 
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influenza virus. The study utilized Cox proportional-hazards modeling to calculate a hazard ratio 
which compares the study groups to placebo. The hazard ratio for time to alleviation of 
symptoms for the 99 subjects in the 300mg Peramivir group and the 97 subjects in the 600mg 
Peramivir group was 0.681 (95% CI:0.511-0.909, p= 0.0092) and 0.666 (95% CI:0.499-0.890, 
p=0.0092), respectively. This is a significant difference showing both groups of Peramivir had 
more of an effect on decreasing the time to alleviation of symptoms in comparison to the placebo 
group. The efficacy is further assessed and compared when viewing the median time, in hours, 
for alleviation of symptoms in each group. The 300mg Peramivir group displayed alleviation 
within a median of 59.1 (95% CI:50.9-72.4) compared to 600mg Peramivir and placebo which 
resulted in 59.9 (95% CI:54.4-68.1) and 81.8 (95% CI: 68.0-101.5), respectively. P- values were 
adjusted and applied to make intergroup comparisons between the Peramivir groups. There was 
no significant difference for efficacy between both dosages of Peramivir which is displayed by 
an adjusted p- value of 0.0092.
4
  
For assessment of safety the Kohno et al
4
 study used the Fischer’s exact test to calculate 
the p- value for comparing Peramivir with placebo groups. All drugs were generally well 
tolerated by all groups and no evidence displayed a significant difference between them. The 
incidence of adverse events compared to placebo was calculated to be P= 0.4986 for the 300mg 
Peramivir group and P= 1.000 for the 600mg Peramivir group. In terms of number of adverse 
events occurring during the study, the Peramivir groups recorded 252 events each while placebo 
recorded 257. The most commonly observed adverse events throughout all groups were 
gastrointestinal. Diarrhea occurred in 14.1% in the 300mg group, 15.2% in the 600mg group, and 
17.0% in the placebo group. There were a total of 10 severe adverse events recorded in all 
groups, with QT prolongation being the most common occurrence (two subjects in the 300mg 
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group, one subject in 600mg group, and three subjects in the placebo).  The 600mg group further 
included one subject developing increased blood glucose and one subject with increased blood 
creatinine. Placebo displayed one subject with increased blood pressure and one subject with 
increased blood glucose.
4
 The relative risk increase, absolute risk increase and numbers needed 
to harm were calculated to be -3.3%, -3%, and -34, respectively (Table 2). 
In the Kohno
5
 study, 1,099 patients were assigned randomly to the three treatment groups 
of 300mg Peramivir, 600mg Peramivir, and 75mg Oseltamivir. Two patients lacked post 
treatment efficacy data and eight patients dropped out before treatment, leaving 1,091 patients in 
the intent to treat population (364 receiving 300mg, 362 receiving 600mg, and 365 receiving 
Oseltamivir). The primary efficacy endpoint was calculated using the Cox proportional-hazards 
model to compare Peramivir groups to Oseltamivir. Noninferiority of the Peramivir groups to 
Oseltamivir was exhibited by hazard ratios of 0.946 (97.5% CI:0.793-1.129) for 300mg 
Peramivir group and 0.970 (97.5% CI:0.814-1.157) for the 600mg Peramivir group. Time to 
alleviation of symptoms, in hours, for the 300mg Peramivir, 600mg Peramivir, and 75mg 
Oseltamivir groups were 78.0 (95% CI:68.4-88.6), 81.0 (95% CI:72.7-91.5), and 81.8 (95% 
CI:73.2-91.1), respectively.
5
  
In terms of safety, Kohno et al
5 
demonstrated incidence of adverse events for the 300mg 
Peramivir, 600mg Peramivir, and Oseltamivir groups as 14.0%, 18.1%, and 20.0%, respectively. 
This showed the 300mg Peramivir group to be significantly safer in terms of adverse events than 
the Oseltamivir group whereas the 600mg Peramivir group was insignificantly less. Adverse 
effects of serious stature were most commonly QT prolongation with no significant difference 
between the three groups. QT prolongation occurred in 5 subjects receiving 300mg Peramivir, 8 
subjects receiving 600mg Peramivir, and 10 subjects receiving Oseltamivir.
5
 As mentioned in 
Phytides, Peramivir for Influenza   9 
 
table 2, the relative risk increase, absolute risk increase, and numbers needed to harm were -22%, 
-15%, -7%, respectively. This negative value for NNH means for every 7 patients who took 
Peramivir 300mg , there was one fewer incidence than those who took Peramivir 600mg. 
Table 2 - Harm effects 
Study CER EER RRI ARI NNH 
Ison et al
1 
73% 79% 8% 6% 17 
Kohno et al
4 
90.9% 87.9% -3.3% -3% -34 
Kohno et al
5 
66% 51% -22% -15% -7 
 
6. Discussion 
  
 The efficacy and safety of 300mg Peramivir was the scope of this review when analyzing 
all three studies. Currently, a single dose of 600mg Peramivir is used for treatment in acute 
uncomplicated influenza in adult patients.
6
 The 600mg Peramivir is directed to be intravenously 
infused for 15-30 minutes.
6
 Thus comparison between the dosages of Peramivir was an important 
aspect to address for consideration of 300mg Peramivir.  
  In Ison et al
1
, 300mg twice daily, Peramivir displayed less median time to alleviation of 
symptoms compared to the 600mg once daily, Peramivir. It can be argued that there is not 
enough statistical evidence in this study to determine a superiority between the two groups since 
the study did not provide p-values.  As far as safety, it seems there is no significance between 
both Peramivir groups. Being this was an open label study, there stood no placebo or baseline to 
compare the data collected.  
 In Kohno et al
4
, both Peramivir groups exhibited statistical evidence of superiority in 
efficacy compared to placebo. The Peramivir groups once again did not show a significant 
difference between each other. As far as safety, all three groups in the study displayed similar 
adverse events.  
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 Kohno et al
5
 study had also displayed superiority of the efficacy endpoint in both 
Peramivir groups in comparison to Oseltamivir. There was not as much statistical significance in 
this study to prove this point compared to the last study mentioned above. The safety endpoint 
showed the most differentiation compared to the other studies. The 300mg Peramivir group had a 
more significant percentage of subjects without adverse events than the Oseltamivir group.  
Limitations were found in the three studies concerning population, exclusion criteria and 
comparison groups. All three studies differed in the populations of subjects with Ison et al
1
 
including the United States, Canada, Mexico, Australia, and New Zealand, Kohno et al
4 
including
 
only Japan, and Kohno et al
5
 focusing on subjects from Japan, South Korea and 
Taiwan. Though Japan was included in two of the three studies this may not provide efficient 
overlap of patient population. Population is important in this review also because of the existence 
of different influenza strains in each region of the world. Keeping this a constant could show 
change in the outcomes and possibly leading to more concise results for specific populations. 
In terms of exclusion criteria, potential limitation could have existed when considering 
protocol taken. In Ison et al
1
 the enrollment criteria was more broad thus leading to the 
possibility of more severely ill patients involved. In Kohno et al
4
, the enrollment criteria was 
more specific and led to exclusion of high risk patient populations. This could have resulted in 
different outcomes for time to alleviation of symptoms due to severely ill patients potentially 
taking longer to resolve symptoms. Also, the criteria of Ison et al
1
 incorporated a population with 
a broader variation in strain. A major portion of the subjects suffered from the 2009 H1N1 
pandemic strain along with subjects infected with seasonal influenza strains.  
7. Conclusion 
 
After analyzing and reviewing the results provided in the three studies, intravenous  
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300mg Peramivir is effective and safe for treatment in seasonal influenza. Though, 300mg 
Peramivir did not show significant evidence of superior efficacy compared to 600mg groups, the 
argument can be made that showing noninferiority is sufficient to allocate further research for the 
use of 300mg Peramivir and show effectiveness. Not all studies provided enough statistical 
evidence to state 300mg Peramivir as the clear leader amongst all comparison groups. To further 
the argument of 300mg Peramivir to be considered as a treatment option, Ison et al
1
 
demonstrated that giving Peramivir at doses of 300mg compared to a single dose of 600mg 
Peramivir for multiple days did result in less time to alleviation of symptoms. By displaying 
noninferiority to 600mg Peramivir and 75mg Oseltamivir, 300mg Peramivir demonstrated an 
ability to be as effective as the treatment options approved at this time. All of the studies showed 
the safety endpoint in all groups were not significant. One group did not seem to exhibit an 
excess of adverse events over the others. 
For future research I would recommend studies to be conducted using populations and 
exclusion criteria that are close in detail. I recommend conducting randomized controlled trials 
that only include either high risk or previously healthy patients from the United States with 
similar influenza strains. In this manner, 300mg Peramivir may be more accurately assessed for 
usage. 
 
 
 
 References  
1. Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in 
hospitalized patients. Antivir Ther (Lond ). 2014;19(4):349-361.  
2. Flu Prevention. CDC Flu Infographic. http://www.cdcfoundation.org/businesspulse/flu-
prevention-infographic. Accessed October 10, 2016 
3. Papadakis M, McPhee S. Seasonal Influenza. In: Rabow M, ed. Current medical diagnosis & 
treatment. Fifty-Fifth ed. ;2016:1387-1393. 2016. 
4. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for 
treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 
2010;54(11):4568-4574.  
5. Kohno S, Yen M, Cheong H, et al. Phase III randomized, double-blind study comparing 
single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus 
infection. 2011 Nov;55(11):5267-5276.  
6. Peramivir. In Lexicom. Lexicomp. http://online.lexi.com/lco/action/doc/retrieve/ 
docid/patch_f/2008559. Accessed December 15
th
, 2016. 
 
